Plasma neurofilament L to amyloid β42 ratio in differentiating Alzheimer’s type from non-Alzheimer’s dementia: A cross-sectional pilot study from India
| Autor: | Sarada Subramanian, Palanimuthu T. Sivakumar, Mathew Varghese, Ajit Bhalchandra Dahale, Susheel Kumar J, Preeti Sinha, Geethu Krishna |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Neurofilament Amyloid Intermediate Filaments Pilot Projects tau Proteins Disease Alzheimer Disease Internal medicine mental disorders medicine Humans Dementia Alzheimer s dementia General Psychology Amyloid beta-Peptides business.industry General Medicine medicine.disease Peptide Fragments Clinical trial Psychiatry and Mental health Neurofilament-L Cross-Sectional Studies Aducanumab business Biomarkers |
| Zdroj: | Asian Journal of Psychiatry. 66:102914 |
| ISSN: | 1876-2018 |
| DOI: | 10.1016/j.ajp.2021.102914 |
| Popis: | Based on the reduction of amyloid β plaques, US FDA has recently approved Aducanumab as a disease modifying treatment for Alzheimer's disease (AD). With high pricing and the potential risks likely with this treatment, certainty of AD diagnosis becomes crucial. The current pilot study evaluated plasma levels of neurofilament L, an axonal injury marker and amyloid β42, a major component of amyloid plaques for discriminating AD from non-AD dementia (NAD). Results with Simoa assays indicate that a combination of neurofilament L and amyloid β42 can be considered as a screening tool in identifying eligible subjects for AD treatment/ clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect